9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NMTR vs. GLTO, TTNP, SBFM, JAGX, MTNB, PRFX, MBIO, THAR, CNSP, and CANFShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Galecto (GLTO), Titan Pharmaceuticals (TTNP), Sunshine Biopharma (SBFM), Jaguar Health (JAGX), Matinas Biopharma (MTNB), PainReform (PRFX), Mustang Bio (MBIO), Tharimmune (THAR), CNS Pharmaceuticals (CNSP), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Galecto Titan Pharmaceuticals Sunshine Biopharma Jaguar Health Matinas Biopharma PainReform Mustang Bio Tharimmune CNS Pharmaceuticals Can-Fite BioPharma 9 Meters Biopharma (NASDAQ:NMTR) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking. Does the MarketBeat Community favor NMTR or GLTO? 9 Meters Biopharma received 5 more outperform votes than Galecto when rated by MarketBeat users. Likewise, 71.15% of users gave 9 Meters Biopharma an outperform vote while only 60.38% of users gave Galecto an outperform vote. CompanyUnderperformOutperform9 Meters BiopharmaOutperform Votes3771.15% Underperform Votes1528.85% GalectoOutperform Votes3260.38% Underperform Votes2139.62% Is NMTR or GLTO more profitable? Galecto's return on equity of -76.96% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets 9 Meters BiopharmaN/A -584.97% -159.45% Galecto N/A -76.96%-66.59% Which has higher valuation & earnings, NMTR or GLTO? Galecto is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/AGalectoN/AN/A-$38.35M-$15.53-0.19 Which has more volatility and risk, NMTR or GLTO? 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Galecto has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Do insiders and institutionals hold more shares of NMTR or GLTO? 22.3% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 2.4% of 9 Meters Biopharma shares are held by company insiders. Comparatively, 10.8% of Galecto shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor NMTR or GLTO? In the previous week, 9 Meters Biopharma's average media sentiment score of 0.00 equaled Galecto'saverage media sentiment score. Company Overall Sentiment 9 Meters Biopharma Neutral Galecto Neutral Do analysts recommend NMTR or GLTO? Galecto has a consensus price target of $10.00, indicating a potential upside of 236.13%. Given Galecto's stronger consensus rating and higher possible upside, analysts clearly believe Galecto is more favorable than 9 Meters Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryGalecto beats 9 Meters Biopharma on 7 of the 13 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$128.99M$5.38B$8.39BDividend YieldN/A3.74%5.21%4.10%P/E Ratio-0.023.4326.8019.71Price / SalesN/A4,162.64389.55117.28Price / CashN/A13.1938.2534.62Price / BookN/A33.146.804.50Net Income-$43.77M-$91.56M$3.23B$248.18M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220GLTOGalecto1.649 of 5 stars$3.07+6.6%$10.00+225.7%-80.9%$4.06MN/A-0.1640Gap DownTTNPTitan Pharmaceuticals0.6002 of 5 stars$4.42-5.4%N/A-31.7%$4.04M$180,000.00-0.9610Analyst ForecastGap UpSBFMSunshine Biopharma1.8322 of 5 stars$1.49-0.7%$15.00+906.7%+76.3%$4.03M$34.87M-0.013Earnings ReportGap DownJAGXJaguar Health1.5899 of 5 stars$5.76-2.0%$60.00+941.7%-98.0%$3.88M$11.69M0.0050Earnings ReportAnalyst ForecastHigh Trading VolumeMTNBMatinas BiopharmaN/A$0.76-12.8%N/AN/A$3.87M$1.10M-0.1630Gap DownPRFXPainReform1.8075 of 5 stars$1.91flat$8.00+318.8%-37.7%$3.85MN/A-0.014MBIOMustang Bio0.3652 of 5 stars$1.16+3.6%N/A-92.3%$3.84MN/A-0.01100Positive NewsGap DownTHARTharimmune1.5371 of 5 stars$1.43+7.8%$17.00+1,085.8%-77.0%$3.82MN/A-0.182Negative NewsCNSPCNS Pharmaceuticals1.3045 of 5 stars$1.29+0.8%$25.00+1,838.0%-99.8%$3.80MN/A-0.025Earnings ReportCANFCan-Fite BioPharmaN/A$1.05-0.5%$14.00+1,239.7%-57.7%$3.72M$674,000.00-0.588 Related Companies and Tools Related Companies GLTO Alternatives TTNP Alternatives SBFM Alternatives JAGX Alternatives MTNB Alternatives PRFX Alternatives MBIO Alternatives THAR Alternatives CNSP Alternatives CANF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
